Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 100 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 880.00 | |
| 500 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 1’700.00 |
Über diesen Artikel
Lineare Formel:
HOOCCH2CH(NHCONH2)COOH
CAS-Nummer:
Molekulargewicht:
176.13
UNSPSC Code:
12352106
NACRES:
NA.25
PubChem Substance ID:
EC Number:
213-096-6
Beilstein/REAXYS Number:
1726861
MDL number:
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Level
assay
98.0-102.0% (T)
mp
~175 °C (dec.)
format
neat
SMILES string
NC(=O)NC(CC(O)=O)C(O)=O
InChI
1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)
InChI key
HLKXYZVTANABHZ-UHFFFAOYSA-N
Biochem/physiol Actions
Metabolite of pyrimidine biosynthesis, alanine, aspartate and glutamate metabolism.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| format neat | format - | format - | format - |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 200 |
| assay 98.0-102.0% (T) | assay ≥98.0% (T) | assay ≥99.0% | assay 88.0-92.0% |
| mp ~175 °C (dec.) | mp 170-175 °C (dec.) | mp 195-210 °C (dec.) | mp - |
Lagerklasse
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
André B P van Kuilenburg et al.
Clinical chemistry, 50(11), 2117-2124 (2004-09-18)
The concentrations of the pyrimidine "de novo" metabolites and their degradation products in urine are useful indicators for the diagnosis of an inborn error of the pyrimidine de novo pathway or a urea-cycle defect. Until now, no procedure was available
L D Fairbanks et al.
Journal of chromatography. B, Biomedical sciences and applications, 732(2), 487-493 (1999-10-12)
Leflunomide is an immunomodulatory drug which acts by inhibiting dihydroorotic acid dehydrogenase, the fourth enzyme of pyrimidine biosynthesis. We modified our high-performance liquid chromatography method to demonstrate that the principal metabolite in mitogen-stimulated human T-lymphocytes incubated with leflunomide was not
Amy J Rice et al.
Analytical biochemistry, 441(1), 87-94 (2013-06-19)
Dihydroorotase (DHOase) is the third enzyme in the de novo pyrimidine biosynthesis pathway and is a potential new antibacterial drug target. No target-based high-throughput screening (HTS) assay for this enzyme has been reported to date. Here, we optimized two colorimetric-based
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 69037-500MG | 04061832404929 |
| 69037-100MG | 04061832404912 |



